SCHEMBL822544

SCHEMBL822544

Cn1nc2ccncc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
NPC1 O15118 2/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
CASP1 P29466 1/20 0.37
ALDH1A1 P00352 3/20 0.36
NFATC1 O95644 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
FGFR1 P11362 1/20 0.36
RPS6KA5 O75582 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
USP2 O75604 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7479573 0.76 GAA (0.33) ATMMAPTALDH1A1FGFR1SMN1; SMN2
SCHEMBL24210738 0.76 USP2 (0.38) ATMNFATC1GSK3BDYRK1AUSP2
SCHEMBL15935292 0.76 LATS1 (0.34) ATMALDH1A1FGFR1
SCHEMBL24669479 0.73 MAPK1 (0.36)
SCHEMBL822547 0.71 SLC9A1 (0.48) ATMNPC1MAPTRAB9ASMN1; SMN2
SCHEMBL822572 0.69 IMPDH2 (0.39) ATMNPC1TP53MAPTRAB9A
SCHEMBL16417560 0.67 MAPT (0.44) ATMMAPTALDH1A1NFATC1GSK3B
SCHEMBL16217170 0.67 MAPT (0.48) ATMNPC1TP53MAPTRAB9A
SCHEMBL256337 0.67 FGFR1 (0.53) ATMNPC1TP53MAPTRAB9A
SCHEMBL10328319 0.67 SLC9A1 (0.55) ATMNPC1TP53MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 EP disclosed
WO-2021121282-A1 PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS WITH IMMUNOMODULATORY FUNCTION 上海轶诺药业有限公司 2021-06-24 WO disclosed
EP-3831824-A1 PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-06-09 EP disclosed
EP-3750909-A1 STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-12-16 EP disclosed
EP-3750908-A1 STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-12-16 EP disclosed
EP-3719030-A1 19-NOR NEUROACTIVE STEROIDS FOR INDUCING SEDATION Sage Therapeutics, Inc. (US) 2020-10-07 EP disclosed
WO-2020156106-A1 HETEROCYCLIC ARYL FORMAMIDES OR SALT THEREOF, PREPARATION METHOD, WEEDING COMPOSITION, AND APPLICATION 青岛清原化合物有限公司 2020-08-06 WO disclosed
EP-2986624-B1 19-NOR NEUROACTIVE STEROIDS FOR METHODS OF TREATMENT SAGE THERAPEUTICS INC (US) 2020-03-25 EP disclosed
WO-2020024997-A1 PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION 上海轶诺药业有限公司 2020-02-06 WO disclosed
US-9745291-B2 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. (US) 2017-08-29 US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 US disclosed
US-9604930-B2 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-03-28 US disclosed
US-20160368907-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-12-22 US disclosed
US-20150361042-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-17 US disclosed
US-20150344433-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF Epizyme, Inc. (US) 2015-12-03 US disclosed
US-20150191432-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-07-09 US disclosed
US-9067919-B2 Use of dibenzofurans and dibenzothiophenes substituted by nitrogen-bonded five-membered heterocyclic rings in organic electronics BASF SE (DE) 2015-06-30 US disclosed
US-8940726-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2015-01-27 US disclosed
US-20120007063-A1 USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS BASF SE (DE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191432-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 ATM 400/4885NPC1 2223/4885TP53 2260/4885
US-20150344433-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF PRMT5, PRMT1, PRMT3 ATM 520/4885NPC1 2846/4885TP53 1917/4885
US-20160368907-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 ATM 400/4885NPC1 2223/4885TP53 2260/4885
US-20150361042-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 ATM 386/4885NPC1 2331/4885TP53 2151/4885
US-20120007063-A1 USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS DDT, DBF4, POU5F1 ATM 4416/4885NPC1 3359/4885TP53 4447/4885
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 ATM 524/4885NPC1 3204/4885TP53 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.